Orally Administered SIRTl Activator SRT501 is Neuroprotective for Retinal Ganglion Cells and Suppresses Neurological Dysfunction in a Mouse Model of Multiple Sclerosis

Update Item Information
Identifier 20080310_nanos_sciplatform_05.pdf
Title Orally Administered SIRTl Activator SRT501 is Neuroprotective for Retinal Ganglion Cells and Suppresses Neurological Dysfunction in a Mouse Model of Multiple Sclerosis
Creator Kenneth S. Shindler; Elvira Ventura; Peter Elliott; A.M. Rostami
Affiliation (KSS) University of Pennsylvania, Philadelphia, PA; (EV) (AMR) Thomas Jefferson University Philadelphia, PA; (PE) Sirtris Pharmaceuticals, Cambridge, MA
Subject Optic Neuritis; Neuroprotection; Retinal Ganglion Cells; Multiple Sclerosis; EAE
Description Neuronal loss in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), correlates with permanent neurological dysfunction. Intravitreal injection of compounds that activate SIRTl, an NAD+-dependent deacetylase involved in cellular stress resistance and survival, attenuates retinal ganglion cell (RGC) loss during acute optic neuritis in EAE mice.
Date 2008-03-10
Language eng
Format application/pdf
Type Text
Source 2008 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2008: Platform Session I
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2010. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6dr61t8
Setname ehsl_novel_nam
ID 180792
Reference URL https://collections.lib.utah.edu/ark:/87278/s6dr61t8
Back to Search Results